AstraZeneca has initiated a clinical study of ticagrelor, an oral antiplatelet treatment for the treatment of acute coronary syndrome.

The double-blind, randomised, three-arm, international, multi-centre and parallel group study will be conducted in 30 countries and enrol approximately 21,000 patients who have experienced a heart attack.

The study is designed to evaluate the safety and efficacy of ticagrelor in this group of patients, and will evaluate if a combination of ticagrelor and aspirin will reduce the risk of subsequent cardiovascular events compared to aspirin-only treatment.

All patients will receive concomitant aspirin therapy (75 to 150mg) and will be also randomised to receive a twice-daily ticagrelor dose of 60mg or 90mg, or a placebo.

The primary efficacy endpoint of the trial will be first occurrence of any cardiovascular event including non-fatal stroke, non-fatal myocardial infarction or cardiovascular death.